View Cart  

French Pathway for Off-Label Prescribing Increases Scrutiny, While Allowing Access

Recent measures in France will broaden risk-benefit scrutiny and expand off-label drugs use in justifiable situations, according to an opinion piece in the Oct. 4 issue of The New England Journal of Medicine.

To View This Article:


Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00